AZD5672 Absolute Bioavailability study
Study identifier:D1710C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I Study to Assess Absolute Bioavailability of AZD5672 at Steady-state in Healthy Volunteers
Medical condition
Healthy Volunteers
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5672
Sex
All
Actual Enrollment
26
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Aug 2008
Primary Completion Date: 01 Jan 2009
Study Completion Date: 01 Jan 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses | Drug: AZD5672 single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period |
| Experimental: 2 2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose | Drug: AZD5672 single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period Drug: AZD5672 50 mg od, 12 days Drug: AZD5672 150mg od, 12 days |
Contacts
Investigators
Principal Investigator
Mark Layton
AstraZeneca R&D, Charnwood, UK
